Patients’ perceptions of nocturnal erectile function assessment with the RigiScan®

Introduction

Erectile dysfunction (ED) is a prevalent condition affecting many men, and its incidence rate increases with age [1, 2]. ED has emerged as an important sentinel marker of cardiovascular and overall health among men [3, 4]. Timely and accurate diagnosis of ED not only facilitates treatment but also offers a valuable opportunity to identify comorbid conditions and potentially life-threatening conditions [5].

The RigiScan® (GoTop Medical, Minneapolis, MN, USA) [6] is a diagnostic tool used to assess erectile function during sleep and is traditionally regarded as the most validated diagnostic procedure for differentiating between psychological and organic causes of ED [5, 7]. The utilization of the RigiScan® has significantly propelled research in the field of ED.

The RigiScan® examination involves wearing a device with two rings around the penis, which is connected to a recording unit. During the night, the device measures changes in penile circumference, rigidity and the duration and frequency of these events, providing healthcare professionals with objective data on nocturnal erections [8, 9]. The data obtained from the RigiScan® examination can assist in the diagnosis and management of ED [9, 10].

While these data have diagnostic value, the use of the RigiScan® has certain disadvantages. Patients may experience discomfort or a sense of awareness while wearing the RigiScan® device while sleeping. The large size of the device and its location on the leg hinders the ability to assume a comfortable lying position. Patients may experience interruptions or awakening due to the device, which can cause an inaccurate representation of nocturnal erections [8, 9, 11]. This discomfort and the potential need for multi-night measurements can impact the accuracy of the data. Furthermore, the RigiScan® is delicate and easily damaged, requiring careful handling and detailed instructions for proper attachment. There is also an issue regarding software compatibility with modern computer operating systems [12].

The clinical utility of the RigiScan® examination has been declining due to these limitations. As a result, there is a growing demand for the development of a new measurement method [13]. Understanding patient experiences with the RigiScan® can provide valuable insight for developing new diagnostic tools that are more comfortable, reliable, and user-friendly.

Aim

The primary aim of this study was to evaluate Dutch patients’ perceptions of the RigiScan® and to explore what patients indicate as advantages and disadvantages of the RigiScan®. The secondary aim was to determine whether there is a need for a new device and what conditions a new device must meet for patient satisfaction.

Materials and methods

From March 2022 until February 2023, a nonvalidated questionnaire with 12 items was mailed to all patients who had a RigiScan® measurement at St. Antonius Hospital and the Leiden University Medical Center (LUMC) between 2016 and February 2023. To obtain a higher response rate, a reminder was sent two weeks later.

The questionnaire was designed by two Dutch sexologists from St. Antonius Hospital in collaboration with two urologists from LUMC involved in andrology and sexual health. There was no validated questionnaire for our research question. The survey questions were pretested through an online survey in seven individuals whose characteristics were similar to those of the sampling frame to ensure relevance and consistency in interpretation, this was done in September 2021. After making changes, with the use of feedback, the questionnaire was pilot tested.

The questionnaire consisted of four parts: (1) age, (2) medical history, (3) user-friendliness, (4) experiences with the RigiScan®, (5) sleep quality, (6) patient-experienced (dis)comfort, and (7) wishes for a new sensor. Some answers could be given on a scale from 0 to 10. The translated questionnaire is available in the Appendix.

Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted at St. Antonius Hospital. REDCap is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture; (2) audit trials for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for data integration and interoperability with external sources [14].

The statistical outcomes were analyzed with IBM SPSS statistics 25 (SPSS Inc., Chicago, IL, USA). The data were analyzed with the use of descriptive statistics. To analyze the relationship between age and the outcomes of difficulty in attaching the device, sleep quality, and pain or discomfort, we used both categorical and continuous representations of age. Age was categorized into three groups: 19–40 years, 40–60 years, and over 60 years. For categorical age groups, we used the Kruskal-Wallis test to assess overall differences between groups. If the Kruskal-Wallis test indicated significant differences, we performed post-hoc pairwise comparisons using the Mann-Whitney U test to identify which specific groups differed.

In addition to categorical analysis, we treated age as a continuous variable to explore its linear relationship with the outcomes. Simple linear regression was conducted to determine whether age could predict the difficulty in attaching the device, sleep quality, and pain or discomfort. Statistical significance was set at a p-value of less than 0.05 for all tests.

The Dutch Medical Ethics Committee was consulted, an application was submitted, and approval was obtained for this study (registered as W19.122 on July 1, 2019). Local approval was received from St. Antonius Hospital (registered as Z19.092 on March 5, 2020) and LUMC (registered as N20.162 on January 4, 2021). All methods were performed in accordance with relevant guidelines and regulations.

Results

Between the first of January 2016 and February 2023, 120 patients underwent a RigiScan® examination for nocturnal erection detection. The questionnaire was sent to all 120 patients. Of these patients, 47 (39.2%) returned completed questionnaires. Three respondents (6.4%) did not answer one of the questions. Informed consent was obtained from all participants through their voluntary participation in the questionnaire.

The mean age of the respondents (at the time of completing the questionnaire) was 39 years with a standard deviation of 16 years (range: 19–73 years). A total of 32 patients (68.1%) reported an absence of comorbidities. Heart and/or vascular disease was reported by six (12.8%), Peyronie’s disease by four (8.5%), diabetes by two (4.3%) and prostate cancer by one (2.1%). None of the respondents reported hypogonadism. Human immunodeficiency virus, granulomatosis with polyangiitis, sleep apnea, depression and muscle stiffness were each reported once as explanations for selecting the answer “other”.

For 45 patients (95.7%), this was the first time that the RigiScan® was used. Two patients had this examination once before. All of the subjects underwent the RigiScan® measurement at home. The majority of patients underwent the RigiScan® examination for one night (n = 20, 42.6%), while 17 patients (36.2%) underwent two nights of examination and 10 patients (21.3%) underwent three nights of examination.

The answers to the question of how complicated it was to attach the RigiScan® to the penis ranged from zero (easy) to ten (very difficult). The average score was 4.6 ± 2.5 (range: 1–9) points. Figure 1 shows a bar chart for the question, “How complicated was it to put the measuring device on the penis?”

Fig. 1: Bar chart for the question, “How complicated was it to put the measuring device on the penis?”
figure 1

On a scale from 0 to 10, where 0 was ‘very easy’, and 10 was ‘very difficult’ (vertical axis). The number of patients is shown on the horizontal axis (missing data of three patients).

Full size image

The majority were able to continue the RigiScan® measurement all night (n = 35, 74.5%). Eight patients mentioned that (one of) the loops slipped off the penis during the night. Two patients removed the RigiScan® loops due to pain or discomfort.

The quality of sleep question was also scaled from zero (no trouble sleeping) to ten (substantial difficulty sleeping). The average response to this question was 5.5 ± 2.6 (range: 0–9) points. (Fig. 2) Sixteen people had trouble sleeping. Ten people slept well or experienced little hindrance. Nine people woke up from pain or tightening of the loops of the RigiScan®. Eight people noted waking up more often and that turning was more difficult due to the part of the RigiScan® that was placed on their leg. Eight people lost the leg attachment for the RigiScan® and/or had trouble keeping the device on the leg. Four people mentioned waking up from the sound of the RigiScan®. Three people mentioned that they could not sleep in their normal position due to the large device. In one person, the loops became loose.

Fig. 2: Bar chart for the question, “How was the quality of sleep during the measurement compared to normal?”
figure 2

On a scale from 0 to 10, where 0 was ‘not bothered by the measurement while sleeping’ and 10 was ‘very bothered by the measurement while sleeping’ (vertical axis). The number of patients is shown on the horizontal axis.

Full size image

In response to the query assessing the level of pain or discomfort on a scale ranging from zero (indicating no pain or discomfort) to ten (representing significant discomfort or pain), participants reported an average rating of 4.7 ± 2.8 (range: 0–9) points. (Fig. 3) Among the respondents, 29.8% (14 individuals) expressed dissatisfaction with the RigiScan®, stating that it did not fulfill their expectations.

Fig. 3: Bar chart for the question, “Can you rate how much pain/discomfort the measurement gave you on a scale of 0 to 10?”, where 0 was ‘not bothered by pain or discomfort’ and 10 was ‘substantial difficulty with the measurement’ (vertical axis).
figure 3

The number of patients is shown on the horizontal axis.

Full size image

The differences was calculated in the difficulty of attaching the device, quality of sleep, and pain or discomfort with age both as categorical (20-40; 40–60; >60) and linear variables (performing a linear regression analysis). The average scores for difficulty in attaching the device, quality of sleep, and pain or discomfort were 3.4, 5.6, and 4.6 for the 19–40 age group (27 patients); 5.1, 4.3, and 3.1 for the 40–60 age group (15 patients); and 6.2, 6.6, and 4.4 for the >60 age group (5 patients). A Kruskal-Wallis test indicated that age, when divided into groups, was a significant predictor of the difficulty in attaching the device (p = 0.049). Subsequent Mann-Whitney tests, however, did not identify significant differences between the specific age groups. Additionally, age was not a significant predictor of sleep quality (p = 0.2) or pain/discomfort (p = 0.4). A simple linear regression analysis indicated that age was a significant predictor of the difficulty in attaching the device (R² = 0.208, p = 0.002), but not a significant predictor of sleep quality (R² = 0.002, p = 0.762) or pain/discomfort (R² = 0.017, p = 0.388).

The most important improvements for a successor of the RigiScan® should concern size (n = 33, 33.6%), user-friendliness (n = 25, 25.5%), noise (n = 9, 9.2%), hygiene (n = 7, 7.1%), pain (n = 6, 6.1%), faster results (n = 4, 4.1%), visibility for the environment (n = 2, 2.0%), and other factors (n = 12, 12.2%) (Table 1). Other improvements suggested by the patients included an indicator light so you know if it is on and if the measurement is done correctly, an increased battery life, decreased heaviness and/or size of the device (three times), increased reliability, decreased pressure on the penis, no cords around the penis, and decreased impact of the measurement protocol on sleep (two times).

Table 1 What are the main conditions that a new sensor to measure nighttime erections must meet?
Full size table

On the question: If a new small and reliable device were to come into the shop to be able to do this measurement anonymously at home, how much money would you pay for this? Forty-two persons answered a number between 0 and 500 euros, and the average amount for a new device was 74 euros. Seventeen people would not pay any money for this. Two persons answered that they were unsure. Three people mentioned that they would only perform this test if it was covered by health care insurance.

Discussion

The focus of this study was on understanding patients’ perspectives on the use of the RigiScan®, a diagnostic tool for assessing ED. Our findings indicate that while the RigiScan® has been valuable in identifying the causes of ED, it has significant drawbacks, particularly regarding patient comfort and usability.

The most noticeable and mentioned drawback of the RigiScan® is the placement of straps and the slipping of straps during nocturnal measurements. This issue was mentioned by 25.5% of the respondents. Another critical factor was the impact on sleep quality, an aspect of overall well-being and a necessity in measuring nocturnal erections. The moderate discomfort (5.5 ± 2.6) mentioned by respondents can lead to disrupted sleep patterns, potentially affecting the accuracy of nocturnal erection measurements. Moreover, respondents rated discomfort/pain at an average of 4.7 ± 2.8 points, highlighting the need for a more gentle and less intrusive measurement.

The results indicate that attaching the device becomes more complicated as patients age, with significant differences observed in the average scores across age groups. The linear regression analysis confirmed that age is a significant predictor of the difficulty in attaching the device, explaining approximately 20.8% of the variance. However, age was not a significant predictor of sleep quality or pain/discomfort, suggesting that these factors are influenced by other variables. The small sample sizes within each age group limit the ability to draw definitive conclusions.

Patients mentioned several areas for improvement, including the desire for a smaller and lighter device. A more compact design could be less disruptive during sleep and more comfortable to wear during the night. They also expressed the need for a device that is easier to use, simplifying the process of using the RigiScan®. Patients suggested the desire for a device that produces minimal noise during the measurement, minimizing any potential disruptions to their sleep or discomfort caused by sounds.

The RigiScan® has long been the gold standard for differentiating between psychological and organic causes of ED [7]. It has been instrumental in diagnosing and understanding ED in men [7]. However, its use is decreasing rapidly due to outdated hardware and software and suboptimal patient experience [12]. This decline in usage and our study’s insights from the patient’s perspective underscore the need to explore alternative diagnostic tools that are more patient-friendly and practical.

In addition to patients, sexologists also acknowledge the issues with the current measurement method. Both groups expressed a shared desire for the improvement of the existing measuring device [13]. A significant proportion of sexologists expressed interest in using a ‘simple sensor’ for ED diagnosis if available [13]. Now that this has been established, hopefully, a more modern sensor can be developed that meets the requirements of both users and sexologists.

Despite the value of this study, there are limitations to consider. The response rate was relatively low at 39%, which may impact the generalizability of the findings. However, it should be noted that the response rate is higher than the average response rate of 30% for email-based questionnaires [15]. The low response rate may be attributed to the inclusion of a large population of non-Dutch speaking patients from the LUMC population. Additionally, the demographic characteristics of the respondents remain unknown, and this lack of information introduces the possibility that compared to the respondents, the nonrespondents may hold different beliefs regarding the RigiScan®, potentially leading to an untestable bias.

Additionally, the time gap between the RigiScan® examination and the survey distribution may have contributed to a lower response rate and could have led to recall bias, affecting the accuracy of the responses.

Given these limitations, further research is needed to confirm whether a new diagnostic device, designed with the improvements identified by patients, can indeed enhance patient satisfaction and lead to more accurate results. Additionally, it would be valuable to conduct this study with a new device to compare patient experiences, sleep quality, and comfort. This research may serve as a basis for further investigations into improving ED diagnosis and management, ultimately benefiting patients seeking treatment for this common condition.

This study revealed that patients who underwent a nocturnal erectile function assessment with the RigiScan® device preferred a more patient-friendly and less invasive diagnostic device. Their feedback emphasizes the importance of developing a compact, quiet, and user-friendly tool for assessing nocturnal erections. Further research is needed to ascertain whether a new sensor encompassing these suggested improvements can enhance patient satisfaction.

Related Articles

Central amygdala somatostatin neurons modulate stress-induced sleep-onset insomnia

Sleep-onset insomnia, characterized by difficulty falling asleep, is linked to increased health risks. Previous studies have shown that the central amygdala (CeA) plays a crucial role in stress regulation, with the somatostatin neurons in the CeA (CeASST+) involved in adaptive stress responses. However, the role of CeASST+ neurons in stress-induced sleep-onset insomnia remains unclear. In this study, we found that the activity of CeASST+ neurons is closely associated with stressful events using fiber photometry in mice. Acute optogenetic activation of CeASST+ neurons induced a rapid transition from non-rapid eye movement (NREM) sleep to wakefulness. Semi-chronic optogenetic and chemogenetic activation of CeASST+ neurons led to prolonged sleep-onset latency and increased wakefulness. Chemogenetic inhibition of these neurons ameliorated sleep-onset insomnia induced by stressful stimuli, but did not affect sleep-wake behavior under physiological conditions. Collectively, our results suggested that CeASST+ neurons are a key neural substrate for modulating stress-induced sleep-onset insomnia, without influencing physiological sleep. These findings highlight CeASST+ neurons as a promising target for treating stress-related sleep-onset insomnia in clinical practice.

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

The individual determinants of morning dream recall

Evidence suggests that (almost) everyone dreams during their sleep and may actually do so for a large part of the night. Yet, dream recall shows large interindividual variability. Understanding the factors that influence dream recall is crucial for advancing our knowledge regarding dreams’ origin, significance, and functions. Here, we tackled this issue by prospectively collecting dream reports along with demographic information and psychometric, cognitive, actigraphic, and electroencephalographic measures in 217 healthy adults (18–70 y, 116 female participants, 101 male participants). We found that attitude towards dreaming, proneness to mind wandering, and sleep patterns are associated with the probability of reporting a dream upon morning awakening. The likelihood of recalling dream content was predicted by age and vulnerability to interference. Moreover, dream recall appeared to be influenced by night-by-night changes in sleep patterns and showed seasonal fluctuations. Our results provide an account for previous observations regarding inter- and intra-individual variability in morning dream recall.

Raptin, a sleep-induced hypothalamic hormone, suppresses appetite and obesity

Sleep deficiency is associated with obesity, but the mechanisms underlying this connection remain unclear. Here, we identify a sleep-inducible hypothalamic protein hormone in humans and mice that suppresses obesity. This hormone is cleaved from reticulocalbin-2 (RCN2), and we name it Raptin. Raptin release is timed by the circuit from vasopressin-expressing neurons in the suprachiasmatic nucleus to RCN2-positive neurons in the paraventricular nucleus. Raptin levels peak during sleep, which is blunted by sleep deficiency. Raptin binds to glutamate metabotropic receptor 3 (GRM3) in neurons of the hypothalamus and stomach to inhibit appetite and gastric emptying, respectively. Raptin-GRM3 signaling mediates anorexigenic effects via PI3K-AKT signaling. Of note, we verify the connections between deficiencies in the sleeping state, impaired Raptin release, and obesity in patients with sleep deficiency. Moreover, humans carrying an RCN2 nonsense variant present with night eating syndrome and obesity. These data define a unique hormone that suppresses food intake and prevents obesity.

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia

X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert. Historically, these patients were treated with frequent doses of oral phosphate supplements and active vitamin D, which was of limited efficiency and associated with adverse effects. However, the management of XLH has evolved in the past few years owing to the availability of burosumab, a fully humanized monoclonal antibody that neutralizes circulating FGF23. Here, we provide updated clinical practice recommendations for the diagnosis and management of XLH to improve outcomes and quality of life in these patients.

Responses

Your email address will not be published. Required fields are marked *